Immunohistochemical ANXA8 expression in malignant ovarian tumors correlated with FIGO stages and tumor progression, and it was revealed as an independent predictor of outcome and survival and a powerful poor prognosis biomarker for these tumors (Gou et al., 2019). This evidence concerns the gene ANXA8 and neoplasm.